Who is sponsoring NCT02822924?

NCT02822924 is sponsored by Chinese University of Hong Kong.

What drugs are being tested in NCT02822924?

Interventions in NCT02822924: Prostate artery embolization (PAE).

What condition does NCT02822924 study?

NCT02822924 studies Benign Prostate Hyperplasia.

Is NCT02822924 still recruiting?

NCT02822924 is currently completed. Last updated 21 October 2022.

Last reviewed 2022-10-21 · How we verify

NCT02822924

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prostate Artery Embolization for Symptomatic Benign Prostatic Hyperplasia

Completed NA Last updated 21 October 2022

What this trial tests

NA trial testing Prostate artery embolization (PAE) in Benign Prostate Hyperplasia in 82 participants. Completed in 10 March 2021.

Timeline

7 October 2013

Primary endpoint
10 March 2021

10 March 2021

Quick facts

Lead sponsor	Chinese University of Hong Kong
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	82
Start date	7 October 2013
Primary completion	10 March 2021
Estimated completion	10 March 2021
Sites	1 location across Hong Kong

Drugs / interventions tested

Prostate artery embolization (PAE)

Conditions studied

Benign Prostate Hyperplasia — all drugs for Benign Prostate Hyperplasia →

Sponsor

Chinese University of Hong Kong

Who can join

Adults 50 to 80, male only, with Benign Prostate Hyperplasia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective is to evaluate the clinical effectiveness and safety of PAE in treating patients with BPH.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Benign Prostate Hyperplasia

Currently open trials in the same condition.

NCT07071207 — Effect of Text Message Reminders on M-ISI Score After Prostate Surgery · NA · recruiting
NCT07283484 — Early Versus Delayed Trial Without Catheter in Men With Acute Urinary Retention. · NA · recruiting
NCT07014969 — En-bloc With Early Apical Release Versus Lobe-by-lobe LASER Enucleation of the Prostate · NA · active not recruiting

Other Chinese University of Hong Kong trials

Trials by the same sponsor.

NCT07508644 — RSV Vaccination to Reduce Recurrent AECOPD · Phase 4 · not yet recruiting
NCT07230457 — Plasma MTB cfDNA Before Bronchoscopy · not yet recruiting
NCT07288671 — Nostalgia Intervention on Alleviating Loneliness Amongst Older Adults · NA · not yet recruiting
NCT07256457 — Postoperative Pulmonary Function Assessment Based on Deep Learning Study · NA · not yet recruiting
NCT06904209 — Can Artificial Intelligence Reduce Consumption of Standard High Volume Bowel Preparation Regimen Among Older Population, · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02822924 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chinese University of Hong Kong
Last refreshed: 21 October 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02822924.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing